MTOR and prostate cancer: Interestingly, treatment of prostate cancer cells with the inhibitor of polymerase II transcriptional activity α-amanitin, which has no effect on classic cytoplasmic mTOR-regulated signalling pathways-autophagy and phagocytosis, abrogated the metabolic reprogramming associated with the transcriptional function of nuclear mTOR observed in these cells61.